培美曲塞二钠(Pemetrexed Disodium Hydrate) - 药物靶点：DHFR x GART x TYMS_在研适应症：转移性非鳞状非小细胞肺癌，不可切除的胸膜恶性间皮瘤，非鳞状非小细胞肺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

MTA、Multitargeted antifolate、PEMETREXED

+ [31]

靶点

DHFR x GART x TYMS

作用方式

抑制剂

作用机制

DHFR抑制剂(二氢叶酸还原酶抑制剂)、GART抑制剂(GAR转化酶抑制剂)、TYMS抑制剂(胸苷酸合成酶抑制剂)

治疗领域

肿瘤呼吸系统疾病其他疾病+ [4]

在研适应症

转移性非鳞状非小细胞肺癌不可切除的胸膜恶性间皮瘤非鳞状非小细胞肺癌+ [27]

非在研适应症

腺癌晚期癌症晚期结直肠腺癌+ [78]

原研机构

Eli Lilly & Co.

在研机构

Fresenius Kabi Deutschland GmbHBaxter Holding BVActavis Group PTC ehf

+ [25]

非在研机构

GSK Plc

Genentech, Inc.

Novartis Pharmaceuticals Corp.

+ [6]

最高研发阶段批准上市

首次获批日期

美国 (2004-02-04),

恶性胸膜间皮瘤

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C20H35N5Na2O13

InChIKeyPXQGZQUWLRLNRX-MYXYZBIASA-N

CAS号357166-29-1

关联

1,122

项与培美曲塞二钠相关的临床试验

NCT06809517

/ Recruiting临床1/2期IIT

A Phase I/II Clinical Study of an Intrathecal Combination of PD-1/VEGF Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis.

Leptomeningeal metastasis, characterized by tumor cells infiltrating and proliferating in the subarachnoid space, represents a distinct pattern of central nervous system involvement and is a fatal complication of malignant tumors. This study is a prospective, single-arm phase I/II clinical trial aimed at evaluating the safety and efficacy of intrathecal PD-1/VEGF bispecific antibodies combined with pemetrexed in treating leptomeningeal metastases from solid tumors, with the goal of identifying more effective treatment options.

开始日期2025-09-01

申办/合作机构

广州医科大学

NCT06809530

/ Recruiting临床1/2期IIT

Intrathecal Administration of Double Checkpoint Inhibition in Combination with Pemetrexed in Patients with Leptomeningeal Metastasis: a Monocentric Phase I/II

The objective of the present study is to evaluate the tolerability, feasibility, safety and therapeutic response of intrathecal administration of double checkpoint inhibition(QL1706) in combination with pemetrexed in patients with leptomeningeal metastasis.

开始日期2025-09-01

申办/合作机构

广州医科大学

NCT06694454

/ Not yet recruiting临床1/2期IIT

Phase I/II Study of Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Background:
Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Surgery to remove the tumors is the standard treatment for people diagnosed with early stages of NSCLC. Despite complete removal of these tumors, many recur (happen again). An FDA-approved drug combination to treat early-stage NSCLC prior to the surgery is durvalumab plus standard chemotherapy. The FDA approved infusion drug azacytidine [AZA] is used to treat several diseases because it can rapidly kill dividing cells (including cancer cells) but it is not approved for NSCLC. An inhaled (aerosolized) form of AZA is also not approved for NSCLC. However, researchers want to know if an inhaled version of AZA can help improve treatment of people with NSCLC because inhaled AZA goes directly into the lungs with limited absorption into the bloodstream.
Objective:
To find the safest and most effective dose of inhaled AZA in participants with early-stage non-small cell lung cancer (NSCLC) that can still be removed by surgery.
Eligibility:
Adults aged 18 and older with operable early-stage NSCLC. Participants will be required to also enroll in NIH protocol 06C0014 which allows for pre- and post-treatment biopsies and bloodwork to be obtained for additional research studies.
Design:
Participants will be screened. They will have a physical exam with blood tests. Their medical records will be reviewed. They will have imaging scans and tests of their heart and lung functions. Participants will be required to have a tissue sample (biopsy) taken of their tumor prior to receiving study drug and again during surgery after Cycle 3; airway tissue biopsies and collection of collect bronchial (lung) fluid may also be done.
Participants will receive the study treatment for 3 cycles. Each cycle is 21 days. They will need to come to the NIH Clinical Center (CC) on days 1-4 of Cycles 1-3.
AZA will be given as a drug mist that can be inhaled (like the type of mist in an asthma inhaler) using a nebulizer at the NIH Clinical Center (CC) for 3 days in a row (consecutive days) during the first week of each cycle. The participant will inhale the AZA drug mist for 20 to 30 minutes each time. Participants will also receive durvalumab and a specific 2-drug assigned chemotherapy by intravenous (IV) infusion on day 4 of each cycle.
Participants will have a follow-up visit 2 weeks after their last dose of study drugs. Then they will have planned surgery to remove the tumors.
Participants will have additional follow-up visits at the NIH CC about 1 and 3 months after the surgery, and then for every 3 months for up to 3 years.
...

开始日期2025-04-29

申办/合作机构

National Cancer Institute

100 项与培美曲塞二钠相关的临床结果

登录后查看更多信息

100 项与培美曲塞二钠相关的转化医学

登录后查看更多信息

100 项与培美曲塞二钠相关的专利（医药）

登录后查看更多信息

4,559

项与培美曲塞二钠相关的文献（医药）

2025-06-01·EUROPEAN JOURNAL OF PHARMACOLOGY

GART promotes multiple myeloma malignancy via tumor stemness mediated by activating the HSP90α/CDK6/β-catenin axis

Article

作者: Shi, Hui ; Wang, Ze ; Wang, Cheng ; Meng, Han ; Lv, Xinyu ; Gu, Chunyan ; Yang, Ye ; Zhou, Lianxin ; Xu, Xiaoning ; Qian, Jinjun ; Sun, Yi

Tumor progression involves the acquisition of progenitor and stem cell-like characteristics. Glycinamide ribonucleotide transformylase (GART) has been studied in solid tumors for its role in promoting cancer cell stemness, but its function in multiple myeloma (MM) remains unclear. This study aims to determine the impact of GART on MM cell proliferation and its potential as a therapeutic target. Elevated GART was associated with MM stem cell-like markers and unfavorable outcomes in MM patients. In vitro experiments using lentivirus-based overexpression and siRNA-mediated knockdown methods demonstrated that GART promoted MM cell proliferation, colony formation, and cell cycle progression. In vivo studies using a chemically induced plasmacytoma mouse model confirmed that GART accelerated MM malignancy. Mechanistic studies revealed that GART binds to and stabilizes the HSP90α protein, thereby upregulating its client protein CDK6. Additionally, GART activated the Wnt/β-catenin pathway, promoting cell proliferation and the expression of stemness genes in MM. Furthermore, a GART inhibitor, pemetrexed (PEM), effectively suppressed cell proliferation and tumor growth in a human cell line-derived xenograft model (CDX). In conclusion, our findings demonstrate that GART promotes MM cell proliferation and tumor stemness by activating the HSP90α/CDK6/β-catenin axis. Targeting GART may be a promising strategy for developing and improving MM treatments.

2025-05-03·Journal of biomolecular structure & dynamics

Structure-based drug discovery to identify SARS-CoV2 spike protein–ACE2 interaction inhibitors

Article

作者: Saluja, Daman ; Chopra, Madhu ; Kant, Ravi ; Kaushik, Rahul

After the emergence of the COVID-19 pandemic in late 2019, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has undergone a dynamic evolution driven by the acquisition of genetic modifications, resulting in several variants that are further classified as variants of interest (VOIs), variants under monitoring (VUM) and variants of concern (VOC) by World Health Organization (WHO). Currently, there are five SARS-CoV-2 VOCs (Alpha, Beta, Delta, Gamma and Omicron), two VOIs (Lambda and Mu) and several other VOIs that have been reported globally. In this study, we report a natural compound, Curcumin, as the potential inhibitor to the interactions between receptor binding domain (RBD(S1)) and human angiotensin-converting enzyme 2 (hACE2) domains and showcased its inhibitory potential for the Delta and Omicron variants through a computational approach by implementing state of the art methods. The study for the first time revealed a higher efficiency of Curcumin, especially for hindering the interaction between RBD(S1) and hACE-2 domains of Delta and Omicron variants as compared to other lead compounds. We investigated that the mutations in the RBD(S1) of VOC especially Delta and Omicron variants affect its structure compared to that of the wild type and other variants and therefore altered its binding to the hACE2 receptor. Molecular docking and molecular dynamics (MD) simulation analyses substantially supported the findings in terms of the stability of the docked complexes. This study offers compelling evidence, warranting a more in-depth exploration into the impact of these alterations on the binding of identified drug molecules with the Spike protein. Further investigation into their potential therapeutic effects in vivo is highly recommended.

2025-05-03·Journal of biomolecular structure & dynamics

In-silico evaluation of Bismurrayaquinone-A phytochemical as a potential multifunctional inhibitor targeting dihydrofolate reductase: implications for anticancer and antibacterial drug development

Article

作者: Qian, Lei ; Wahab, Shadma ; Li, Shao-Ji ; Alqarni, Mohammed H. ; Almoyad, Mohammad Ali Abdullah ; Alshmmari, Sultan K. ; Alsayari, Abdulrhman ; Khalid, Mohammad

Dihydrofolate reductase (DHFR) has gained significant attention in drug development, primarily due to marked distinctions in its active site among different species. DHFR plays a crucial role in both DNA and amino acid metabolism by facilitating the transfer of monocarbon residues through tetrahydrofolate, which is vital for nucleotide and amino acid synthesis. This considers its potential as a promising target for therapeutic interventions. In this study, our focus was on conducting a virtual screening of phytoconstituents from the IMPPAT2.0 database to identify potential inhibitors of DHFR. The initial criterion involved assessing the binding energy of molecules against DHFR and we screened top 20 compounds ranging energy -13.5 to -11.4 (kcal/Mol) while Pemetrexed disodium bound with less energy -10.2 (kcal/Mol), followed by an analysis of their interactions to identify more effective hits. We prioritized IMPHY007679 (Bismurrayaquinone-A), which displayed a high binding affinity and crucial interaction with DHFR. We also evaluated the drug-like properties and biological activity of IMPHY007679. Furthermore, MD simulation was done, RMSD, RMSF, Rg, SASA, PCA and FEL explore the time-evolution impact of IMPHY007679 comparing it with a reference drug, Pemetrexed disodium. Collectively, our findings suggest that IMPHY007679 recommend further investigation in both in vitro and in vivo settings for its potential in developing anticancer and antibacterial therapies. This compound holds promise as a valuable candidate for advancing drug research and treatment strategies.

1,274

项与培美曲塞二钠相关的新闻（医药）

2025-04-25

·美通社

强生宣布锐珂®（埃万妥单抗注射液）联合化疗方案在华获批用于EGFR TKI经治后局部晚期或转移性非小细胞肺癌患者治疗

MARIPOSA -2 III期研究显示，埃万妥单抗联合化疗与单独化疗组相比中位 PFS显著获益，可将疾病进展或死亡风险降低 52% [ 1] 。其中亚洲亚组数据表明亚洲人群研究者评估中位 PFS为10.3个月 [ 2 , 3] 北京 2025年4月25日 /美通社/ -- 强生公司今日宣布，旗下创新治疗药物锐珂 ® （埃万妥单抗注射液）正式获得国家药品监督管理局批准，与卡铂和培美曲塞联合给药，适用于治疗携带表皮生长因子受体（EGFR）19号外显子缺失或21号外显子L858R置换突变且在EGFR酪氨酸激酶抑制剂治疗期间或之后疾病进展的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）成人患者 [1] 。此次获批标志着埃万妥单抗在中国迎来了今年第二个肺癌适应症。此前，锐珂 ® 已于今年2月获批用于治疗携带EGFR 20号外显子插入突变的局部晚期或转移性非小细胞肺癌成人患者的一线治疗 [1] 。此次获批是基于MARIPOSA-2 III期研究强有力的有效性和安全性数据。研究结果表明，与单独化疗组相比，埃万妥单抗联合化疗可将疾病进展或死亡风险降低52%，中位无进展生存期（PFS）为6.3个月，而单独化疗组为4.2个月（HR=0.48；95%CI：0.36–0.64；P<0.001） [1] 。研究同时观察到，MARIPOSA-2 亚洲亚组人群中，与单独化疗相比，研究者评估中位PFS为10.3个月，而单独化疗组为4.2个月（HR=0.39；95%CI：0.26–0.59；P<0.0001） [2],[3] 。值得注意的是，基于MARIPOSA-2临床试验结果，美国国家综合癌症网络《NCCN临床实践指南》推荐埃万妥单抗联合化疗作为经典EGFR突变晚期NSCLC患者接受奥希替尼治疗进展后的唯一1类优选治疗方案 [4] 。肺癌在我国所有恶性肿瘤中发病率和死亡率均居首位 [5] 。据统计，我国每年肺癌的新发病例超过100万例，占全球肺癌患者总数的三分之一以上 [6],[7] 。EGFR基因突变是非小细胞肺癌中最常见的驱动基因，我国约有40%的患者携带这一突变类型 [8] 。EGFR经典突变类型繁多，其中19外显子缺失和21外显子L858R点突变是EGFR最常见的突变类型 [9] 。据统计，接受EGFR酪氨酸激酶抑制剂（TKI）治疗的EGFR突变晚期非小细胞肺患者，其5年生存率低于20% [10],[11] 。既往接受EGFR TKI单药治疗后出现的获得性耐药机制多种多样且呈多克隆性。这使得疾病进展后的靶向治疗更加困难，从而限制了靶向治疗的疗效 [12],[13] ，而在化疗的基础上联合免疫治疗也未能显示出具有临床意义的改善 [14],[15] 。因此，对于EGFR TKI治疗后疾病进展的EGFR突变非小细胞肺癌患者来说，埃万妥单抗联合化疗方案的出现为这部分患者提供了一个重要的全新治疗选择。强生创新制药中国区总裁Cherry Huang女士表示："锐珂 ® 新适应症的获批对于EGFR TKI经治的EGFR经典突变患者是一项突破性的创新治疗选择。它以显著的临床优势有效填补了这部分患者亟待满足的临床需求，也借助新适应症的拓展服务于更广泛的EGFR突变非小细胞肺癌患者，推动行业开启全新的双抗治疗时代。在强生创新制药迎来在华四十周年之际，我们也承诺将继续携手多方，在提供创新解决方案的同时，满足患者从治疗到社会支持的全方位需求，加速构建'以患者为中心'的医疗生态体系，助力更多患者回归正常生活。" 埃万妥单抗联合化疗的安全谱与既往单药治疗的安全谱一致，因治疗相关不良反应而导致停药的患者比例为10% [1] 。 [1] RYBREVANT China Prescribing Information, April 2025. [2] Passaro A et al. Ann Oncol. 2023.doi: 10.1016/j.annonc.2023.10.117. [3] Jin-Yuan Shih,et al 2023 ESMO ASIA [4] Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for Non-Small Cell Lung Cancer V.9.2024. © National Comprehensive Cancer Network, Inc. All rights reserved. To view the most recent and complete version of the guideline, go online to NCCN.org. Accessed September 2024. [5] Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024,4(1): page. [6] World Health Organization. International Agency for Research on Cancer. China Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/populations/160-china-fact-sheet.pdf. Accessed May 2024. [7] World Health Organization. International Agency for Research on Cancer. All Cancers Fact Sheet. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/39-all-cancers-fact-sheet.pdf. Accessed May 2024. [8] Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget . 2016;7(48):78985-78993. [9] American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed June 2024. [10] Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site. [11] Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol . 2016 Apr;11(4):556-65. [12] Koulouris A, et al. Resistance to TKIs in EGFR-mutated non-small cell lung cancer: from mechanisms to new therapeutic strategies. Cancers (Basel). 2022 Jul 8;14(14):3337. doi: 10.3390/cancers14143337. PMID: 35884398; PMCID: PMC9320011. [13] Aredo JV, et al. Afatinib after progression on osimertinib in EGFR-mutated non-small cell lung cancer. Cancer Treat Res Commun . 2022;30:100497. doi: 10.1016/j.ctarc.2021.100497. [14] Mok TSK, et al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722. Abstract. Ann Oncol . 2022;33(9):S1561-S1562. [15] Yang JCH, et al. Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. Abstract. J Clin Oncol . 2023.41(17): doi:10.1200/JCO.2023.41.17_suppl.LBA9000.

临床结果临床3期免疫疗法

2025-04-25

·Insight数据库

康方「依沃西单抗」第 2 项适应症获批上市，一线治疗 NSCLC！

4 月 25 日，NMPA 官网显示，康方生物全球首创双特异性抗体新药「依沃西单抗」新适应症获批上市，单药用于 PD-L1 表达阳性（PD-L1 TPS≥1%）的局部晚期或转移性非小细胞肺癌（NSCLC）的一线治疗（受理号：CXSS2400080）。此前该上市申请曾被纳入优先审评。截图来自：NMPA 官网2024 年 5 月，依沃西单抗首次获批上市，适应症为联合培美曲塞和卡铂用于经 EGFR-TKI 治疗后进展的 EGFR 基因突变阳性的局部晚期或转移性非鳞状 NSCLC 患者的二线治疗。依沃西单抗是一款 PD-1/VEGF 双特异性抗体，在 2022 年 12 月与 Summit Therapeutics 达成协议以 50 亿美元总额实现 License out 交易，罕见高额引起行业震动。基于康方 Tetrabody 技术设计，依沃西单抗可阻断 PD-1 与 PD-L1 和 PD-L2 的结合，并同时阻断 VEGF 与 VEGF 受体的结合。其抗 PD-1 端采用派安普利单抗的结构，抗 VEGF 端则采用贝伐珠单抗结构。此次依沃西新适应症获批上市是基于 HARMONi-2（AK112-303）研究。这是一项在 PD-L1 表达阳性的局部晚期或转移性 NSCLC 中，依沃西单抗与帕博利珠单抗作为一线治疗的头对头研究。在 2024 年 WCLC 大会上，康方公布该试验的阳性结果。数据显示，依沃西单抗组和帕博利珠单抗组的 mPFS 分别为 11.14 个月和 5.82 个月；依沃西单抗治疗组疾病进展/死亡风险降低达 49%。依沃西单抗相比帕博利珠单抗，显著提高了 PD-L1 阳性 NSCLC 患者一线治疗的客观缓解率（50.0% vs 38.5%）和疾病控制率（89.9% vs 70.5%）。截图来自：2024 WCLC ePoster/Slides在不同 PD-L1 表达水平的人群中，依沃西单抗疗效更为显著：在 PD-L1 TPS ≥50% 人群中，依沃西相比帕博利珠单抗的 PFS HR 达 0.46，疾病进展/死亡风险降低 54%。在 PD-L1 TPS 1-49% 人群中，依沃西相比帕博利珠单抗的 PFS HR 达 0.54，疾病进展/死亡风险降低 46%。各亚组分析显示，无论是鳞癌、非鳞癌患者，还是有无肝转移、脑转移的患者，依沃西单抗均展现了强阳性的疗效：在鳞状非小细胞肺癌人群中，依沃西相比帕博利珠单抗的 PFS HR 达0.48；在非鳞状非小细胞肺癌人群中，依沃西相比帕博利珠单抗的 PFS HR 达 0.54。依沃西相比帕博利珠单抗治疗有脑转移人群的 PFS HR 达 0.55，治疗无脑转移人群的 PFS HR 达 0.53；依沃西相比帕博利珠单抗治疗有肝转移人群的 PFS HR 达 0.47；治疗无肝转移人群的 PFS HR 达 0.53。此外，依沃西单抗组的总体安全性良好，未出现新的安全性信号。依沃西单抗因此成为全球首个且唯一在 III 期单药头对头临床研究中疗效显著优于帕博利珠单抗的药物。Insight 数据库显示，截至目前依沃西单抗已开展了 5 项头对头 PD-1/L1 的 III 期临床，分别为：依沃西单抗+化疗 vs 替雷利珠单抗+化疗一线治疗局部晚期或转移性鳞状 NSCLC （HARMONi-6，NCT05840016）；依沃西单抗+化疗 vs 帕博利珠单抗+化疗一线治疗转移性鳞状 NSCLC（HARMONi-3，NCT05899608）；依沃西单抗+化疗 vs 度伐利尤单抗+化疗一线治疗晚期胆道癌（HARMONi-GI-01，NCT06591520）。依沃西单抗 vs 帕博利珠单抗用于 PD-L1 高表达 (TPS ≥ 50%) 转移性 NSCLC 患者一线治疗（HARMONi-7，NCT06767514）；依沃西单抗 vs 帕博利珠单抗一线治疗 PD-L1 阳性（TPS ≥1%）的局部晚期或转移性 NSCLC（HARMONi-2，NCT05499390）。截图来自：Insight 数据库封面来源：企业 Logo免责声明：本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。编辑：ccaiPR 稿对接：微信 insightxb投稿：微信 insightxb；邮箱 insight@dxy.cn

优先审批上市批准引进/卖出临床结果临床3期

2025-04-25

·医药魔方Info

强生重磅肺癌新药在华获批新适应症

4月25日，强生宣布EGFR/c-MET双抗锐珂（埃万妥单抗）获NPMA批准新适应症的上市申请均已获得国家药监局批准，与卡铂和培美曲塞联合给药，适用于治疗携带表皮生长因子受体（EGFR）19号外显子缺失或21号外显子L858R置换突变且在EGFR酪氨酸激酶抑制剂治疗期间或之后疾病进展的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）成人患者。埃万妥单抗是一种靶向作用于EGFR耐药突变、MET突变和扩增的双特异性抗体，可以同时结合EGFR和c-Met的胞外结构，阻断配体与EGFR和MET的结合，促进受体降解，还可触发抗体依赖性细胞毒性。今年2月，埃万妥单抗已在华获批用于治疗携带EGFR 20号外显子插入突变的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。此次获批是基于MARIPOSA-2 III期研究的数据。结果表明，与单独化疗组相比，埃万妥单抗联合化疗可将疾病进展或死亡风险降低52%，中位无进展生存期（PFS）为6.3个月，而单独化疗组为4.2个月。研究同时观察到，MARIPOSA-2 亚洲亚组人群中，与单独化疗相比，研究者评估中位PFS为10.3个月，而单独化疗组为4.2个月。基于MARIPOSA-2临床试验结果，美国国家综合癌症网络《NCCN临床实践指南》推荐埃万妥单抗联合化疗作为经典EGFR突变晚期NSCLC患者接受奥希替尼治疗进展后的唯一1类优选治疗方案。Copyright © 2025 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

临床3期上市批准临床结果引进/卖出

100 项与培美曲塞二钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	培美曲塞二钠	L01BA04	DB00642

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
转移性非鳞状非小细胞肺癌	美国	Hospira, Inc.	2022-06-10
不可切除的胸膜恶性间皮瘤	欧盟	Sandoz GmbH	2015-09-18
不可切除的胸膜恶性间皮瘤	冰岛	Sandoz GmbH	2015-09-18
不可切除的胸膜恶性间皮瘤	列支敦士登	Sandoz GmbH	2015-09-18
不可切除的胸膜恶性间皮瘤	挪威	Sandoz GmbH	2015-09-18
非鳞状非小细胞肺癌	美国	Eli Lilly & Co.	2009-07-02
间皮瘤	美国	Eli Lilly & Co.	2004-08-19
非小细胞肺癌	美国	Eli Lilly & Co.	2004-08-19
局部晚期非小细胞肺癌	澳大利亚	Eli Lilly Australia Pty Ltd.	2004-06-30
转移性非小细胞肺癌	澳大利亚	Eli Lilly Australia Pty Ltd.	2004-06-30
恶性胸膜间皮瘤	美国	Eli Lilly & Co.	2004-02-04

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
KRAS G12C突变非小细胞肺癌	临床3期	美国	Eli Lilly & Co.	2023-12-21
KRAS G12C突变非小细胞肺癌	临床3期	中国	Eli Lilly & Co.	2023-12-21
KRAS G12C突变非小细胞肺癌	临床3期	日本	Eli Lilly & Co.	2023-12-21
KRAS G12C突变非小细胞肺癌	临床3期	澳大利亚	Eli Lilly & Co.	2023-12-21
KRAS G12C突变非小细胞肺癌	临床3期	奥地利	Eli Lilly & Co.	2023-12-21
KRAS G12C突变非小细胞肺癌	临床3期	比利时	Eli Lilly & Co.	2023-12-21
KRAS G12C突变非小细胞肺癌	临床3期	巴西	Eli Lilly & Co.	2023-12-21
KRAS G12C突变非小细胞肺癌	临床3期	加拿大	Eli Lilly & Co.	2023-12-21
KRAS G12C突变非小细胞肺癌	临床3期	捷克	Eli Lilly & Co.	2023-12-21
KRAS G12C突变非小细胞肺癌	临床3期	丹麦	Eli Lilly & Co.	2023-12-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03137771 (NRG-LU002, CTgov)	临床2期	转移性非小细胞肺癌 \| 复发性非小细胞肺癌	218	Erlotinib Hydrochloride+Gemcitabine+Docetaxel+pembrolizumab+Pemetrexed Disodium (Arm 1 (Systemic Maintenance Chemotherapy))	襯鑰糧遞獵窪齋壓願繭(顧窪築淵夢構觸糧願廠) = 衊選膚遞齋餘簾餘繭願醖獵顧範顧鏇網醖醖餘 (網鏇鹽繭膚鹽衊鹹窪夢, 鏇淵醖築壓鏇膚願廠範 ~ 積願鬱壓窪遞選製鬱選) 更多	-	2025-03-11
				Stereotactic Body Radiation Therapy (SBRT)+Erlotinib Hydrochloride+Gemcitabine+Docetaxel+pembrolizumab+Pemetrexed Disodium (Arm 2 (LCT + Systemic Maintenance Chemotherapy))	襯鑰糧遞獵窪齋壓願繭(顧窪築淵夢構觸糧願廠) = 獵壓製獵網窪艱壓網範醖獵顧範顧鏇網醖醖餘 (網鏇鹽繭膚鹽衊鹹窪夢, 窪遞廠膚壓顧選顧憲積 ~ 網範齋積繭選壓夢鹹衊) 更多
NCT04158141 (CTgov)	临床3期	恶性胸膜间皮瘤	16	Pleurectomy+Carboplatin+Pemetrexed+cisplatin+Pemetrexed Disodium (Arm I (Step 1: Chemotherapy, P/D: Step 2: no Treatment))	製選餘醖顧醖衊觸鏇襯 = 選鏇願壓夢壓鏇壓範範憲糧醖鹽鹹艱襯鹹鏇糧 (鬱襯遞鏇積襯齋範構遞, 繭襯遞憲鹹顧窪鹽鹹蓋 ~ 糧願網憲選醖蓋製壓淵) 更多	-	2025-02-19
				Intensity-Modulated Radiation Therapy+Carboplatin+Pemetrexed+cisplatin+Pemetrexed Disodium (Arm II (Step 1: Chemotherapy, P/D, Step 2: IMRT/PBS))	製選餘醖顧醖衊觸鏇襯 = 網構壓齋簾範窪觸壓網憲糧醖鹽鹹艱襯鹹鏇糧 (鬱襯遞鏇積襯齋範構遞, 齋繭齋築窪鬱淵膚餘夢 ~ 築窪獵網齋選壓築餘築) 更多
NCT05786430 (LUCAS, ESMO_ASIA2024) 人工标引	临床2期	EGFR突变的非小细胞肺癌 EGFR Mutation	54	Lazertinib + Pemetrexed + Carboplatin	範膚鑰選顧齋遞艱獵構(築夢艱廠構願範顧築築) = 選憲積築築網蓋淵鑰選網範製醖獵夢願鑰廠鹹 (築鏇網遞壓觸餘衊醖觸, 5.16 ~ 9.56) 更多	积极	2024-12-07
CTRI/2022/08/044939 (ESMO_ASIA2024) 人工标引	临床2期	原发性腹膜癌 \| 卵巢上皮癌	63	Pemetrexed 500 mg/m2	鹹築願鏇鹹壓築鑰憲鹽(觸淵襯憲鑰壓鏇齋壓鏇) = 淵網願願蓋簾選積鹹淵醖膚鹽醖淵憲繭糧醖憲 (壓鏇構積壓蓋蓋簾廠鬱 ) 更多	积极	2024-12-07
NCT04964960 (CTgov)	临床2期	代谢综合征 \| 非小细胞肺癌 \| 脑转移瘤	3	nab paclitaxel+Carboplatin+Paclitaxel+Pembrolizumab+Pemetrexed	襯積顧蓋選憲選窪積廠 = 遞餘繭範衊網壓繭鬱窪鏇鬱鏇齋鬱觸蓋淵艱選 (淵夢廠窪製衊艱觸壓鹹, 窪壓築製積繭鑰簾顧願 ~ 淵獵醖鹽餘鑰餘鏇壓製) 更多	-	2024-10-21
NCT01088906 (Phalcis, CTgov)	临床2期	晚期肺非小细胞鳞癌 \| 非鳞状非小细胞肺癌	57	Cisplatin+Pemetrexed (EXPERIMENTAL ARM)	衊鹽餘壓糧餘觸顧窪鬱 = 鏇範築餘網選鹽築築簾廠範糧鑰積壓觸鑰廠襯 (簾膚憲憲夢遞構製遞築, 鏇選衊窪製選襯襯選製 ~ 艱繭製鬱壓憲鑰餘願蓋) 更多	-	2024-10-15
				Cisplatin+Pemetrexed (Experimental Arm: Pemetrexed Plus Cisplatin)	衊蓋製醖簾壓鏇鑰壓鹽(壓選衊獵觸鬱鹽製觸積) = 遞鑰鬱鏇製範積選繭築鹹襯壓鏇選憲衊鹹鬱憲 (繭衊餘網醖遞鏇憲獵醖, 積遞鹽膚窪淵繭積構淵 ~ 齋繭鹹齋範鑰鬱糧獵願) 更多
WCLC2024 人工标引	N/A	恶性胸膜间皮瘤二线 \| 一线	267	Nivolumab pNivolumabmumabIpilimumabpemetrexed	齋築餘網製積鏇醖築齋(獵鏇構積鑰簾廠艱膚蓋) = 壓鬱遞鑰構鏇願廠壓醖鏇積廠廠淵鑰壓齋醖艱 (憲鏇齋製廠構壓繭齋鏇, 7.7 ~ 8.5)	积极	2024-09-09
NCT04335292 (OCELOT, WCLC2024) 人工标引	临床2期	EGFR突变肺癌二线 EGFR Mutation	29	Platinum Pemetrexedpemetrexed	鏇繭鏇繭鑰淵簾淵鬱網(夢鑰鏇選憲齋鬱築願獵) = 餘廠構鏇糧艱製觸膚範餘鑰願範顧鑰構範願遞 (範淵鬱鹽遞網願壓醖顧 ) 更多	积极	2024-09-08
				platinum (carboplatin or cisplatin) + pemetrexed (uncommon EGFR mutations)	鏇繭鏇繭鑰淵簾淵鬱網(夢鑰鏇選憲齋鬱築願獵) = 鹹觸鹽製製願衊簾淵構餘鑰願範顧鑰構範願遞 (範淵鬱鹽遞網願壓醖顧 ) 更多
NCT04035486 (FLAURA2, CTgov)	临床3期	EGFR阳性非小细胞肺癌	587	Carboplatin+Pemetrexed+AZD9291 (Safety Run-In: AZD9291 + Carboplatin + Pemetrexed)	糧膚鬱繭鬱積壓壓鏇壓 = 築衊齋壓積衊網觸獵淵窪製獵醖獵壓觸觸製鹽 (積鑰構膚選積網鹹憲鑰, 願網憲獵憲獵獵廠糧遞 ~ 齋鑰齋夢獵壓鏇網網餘) 更多	-	2024-08-06
				Pemetrexed+Cisplatin+AZD9291 (Safety Run-In: AZD9291 + Cisplatin + Pemetrexed)	糧膚鬱繭鬱積壓壓鏇壓 = 獵衊淵遞選鏇餘糧廠構窪製獵醖獵壓觸觸製鹽 (積鑰構膚選積網鹹憲鑰, 壓繭鏇蓋襯餘鬱膚齋夢 ~ 繭壓繭襯顧壓積獵憲鑰) 更多
NCT00998166 (CTgov)	临床2期	晚期肺非鳞状非小细胞癌	12	Bevacizumab+cisplatin+pemetrexed	觸壓鏇衊廠繭範鏇糧顧(糧鹽壓鏇壓衊顧壓簾鏇) = 糧憲壓範選糧餘繭襯鬱製製壓鏇齋衊齋鹽廠衊 (築衊構衊襯廠夢膚鏇糧, 窪鏇鹽壓簾鏇窪鹹構夢 ~ 築鹹築鹽餘願獵鏇夢願) 更多	-	2024-07-30